
In recent years, major advances in research and experimental approaches have significantly increased our knowledge on the role of the HIV-1 capsid in the virus life cycle, from reverse transcription to integration and gene expression. This makes the capsid protein a good pharmacological target to inhibit HIV-1 replication. This review covers our current understanding of the role of the viral capsid in the HIV-1 life cycle and its interaction with different host factors that enable reverse transcription, trafficking towards the nucleus, nuclear import and integration into host chromosomes. It also describes different promising small molecules, some of them in clinical trials, as potential targets for HIV-1 therapy.
Cell Nucleus, Virus Integration, Active Transport, Cell Nucleus, integration, HIV Infections, Review, reverse transcription, Virus Replication, Microbiology, drugs, QR1-502, nuclear entry, Capsid, Host-Pathogen Interactions, capsid, HIV-1, Humans, Capsid Proteins
Cell Nucleus, Virus Integration, Active Transport, Cell Nucleus, integration, HIV Infections, Review, reverse transcription, Virus Replication, Microbiology, drugs, QR1-502, nuclear entry, Capsid, Host-Pathogen Interactions, capsid, HIV-1, Humans, Capsid Proteins
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 15 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
